ACAD
Price
$23.56
Change
+$0.16 (+0.68%)
Updated
Sep 22, 6:59 PM EST
44 days until earnings call
CRSP
Price
$45.49
Change
-$0.57 (-1.24%)
Updated
Sep 22, 6:59 PM EST
38 days until earnings call

Analysis and predictions ACAD vs CRSP

Header iconACAD vs CRSP Comparison
Open Charts ACAD vs CRSPBanner chart's image
ACADIA Pharmaceuticals
Price$23.56
Change+$0.16 (+0.68%)
Volume$1.11M
CapitalizationN/A
CRISPR Therapeutics AG
Price$45.49
Change-$0.57 (-1.24%)
Volume$330.85K
CapitalizationN/A
View a ticker or compare two or three
ACAD vs CRSP Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ACAD vs. CRSP commentary
Sep 24, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and CRSP is a Hold.

COMPARISON
Comparison
Sep 24, 2023
Stock price -- (ACAD: $23.56 vs. CRSP: $45.49)
Brand notoriety: ACAD and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 114% vs. CRSP: 68%
Market capitalization -- ACAD: $3.86B vs. CRSP: $3.61B
ACAD [@Biotechnology] is valued at $3.86B. CRSP’s [@Biotechnology] market capitalization is $3.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $410.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACAD and CRSP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 6 bearish.
  • CRSP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -4.69% price change this week, while CRSP (@Biotechnology) price change was -10.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.79%. For the same industry, the average monthly price growth was +32.38%, and the average quarterly price growth was +31.88%.

Reported Earning Dates

ACAD is expected to report earnings on Nov 06, 2023.

CRSP is expected to report earnings on Nov 01, 2023.

Industries' Descriptions

@Biotechnology (-4.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ACAD with price predictions.
OPEN
A.I.dvisor published
a Summary for CRSP with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ACAD($3.86B) has a higher market cap than CRSP($3.61B). ACAD YTD gains are higher at: 47.990 vs. CRSP (11.907). ACAD has higher annual earnings (EBITDA): -124.29M vs. CRSP (-452.76M). CRSP has more cash in the bank: 1.77B vs. ACAD (375M). ACAD has less debt than CRSP: ACAD (58.8M) vs CRSP (245M). ACAD has higher revenues than CRSP: ACAD (551M) vs CRSP (170M).
ACADCRSPACAD / CRSP
Capitalization3.86B3.61B107%
EBITDA-124.29M-452.76M27%
Gain YTD47.99011.907403%
P/E RatioN/A20.92-
Revenue551M170M324%
Total Cash375M1.77B21%
Total Debt58.8M245M24%
FUNDAMENTALS RATINGS
ACAD vs CRSP: Fundamental Ratings
ACAD
CRSP
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
5263
P/E GROWTH RATING
1..100
10078
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (67) in the Biotechnology industry is in the same range as CRSP (68). This means that ACAD’s stock grew similarly to CRSP’s over the last 12 months.

ACAD's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as CRSP (100). This means that ACAD’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as ACAD (95). This means that CRSP’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's Price Growth Rating (52) in the Biotechnology industry is in the same range as CRSP (63). This means that ACAD’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as ACAD (100). This means that CRSP’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADCRSP
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 13 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CSQ14.490.07
+0.49%
Calamos Strategic Total Return
HFXI23.400.02
+0.09%
IQ FTSE International Eq Ccy Netrl ETF
XDOC25.000.01
+0.06%
Innovator US Equity Accelerated ETF Oct
FCPI32.27-0.02
-0.06%
Fidelity® Stocks for Inflation ETF
SPXE91.62-0.26
-0.29%
ProShares S&P 500® ex-Energy

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with AGIO. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+0.68%
AGIO - ACAD
46%
Loosely correlated
-1.49%
RARE - ACAD
45%
Loosely correlated
-0.49%
DNLI - ACAD
42%
Loosely correlated
-1.51%
FOLD - ACAD
41%
Loosely correlated
+0.41%
RGNX - ACAD
41%
Loosely correlated
-2.89%
More